Introducción: los inhibidores de la bomba de protones (IBP) bloquean la enzima H + /K + ATPasa en las células parietales gástri-cas, logrando la inhibición de la secreción de ácido clorhídrico de forma basal como tras estimulación. Las indicaciones apropiadas para su uso son: enfermedad por reflujo gastroesofágico, hemorragia digestiva aguda, úlceras activas, gastritis o esofagitis erosiva, dispepsia, gastropatía por AINE, profilaxis de úlcera de estrés en pacientes de riesgo.
INTRODUCTION
Proton pump inhibitors (PPIs) are drugs based on a benzimidazolic group with high affinity and inhibiting activity that blocks the H cells. Because of their basic character they remain in a higher concentration for a longer time in an acid environment. Thus, inhibition remains both in baseline conditions and in response to stimuli even when H 2 -receptor antagonists or muscarinic receptor antagonists fail (1, 2) . This is the reason why PPIs are widely used both in inpatient and outpatient treatments.
PPIs may have some adverse effects such as gastrointestinal symptoms (< 3%) (nausea, diarrhea, abdominal pain), musculoskeletal pain, and less frequently (< 0.7%), rash, lichenoid dermatitis, peripheral neuropathy, gynecomastia, and hemolytic anemia. In addition, PPIs present some interactions with other drugs such as warfarin, diazepam, and phenytoin, because all of them are metabolized via the cytochrome P-450 system. In these cases special care is needed with treatments in order to avoid potential problems (1, 2) .
Even though the indications for PPI prescription are well defined (1) (2) (3) (4) , these indications are often ignored (Table I ). Some studies demonstrate their overuse (3-7) in some cases, including stress ulcer prophylaxis in low-risk patients or concomitant prescription with corticosteroids (8, 9) .
The aim of our study was to review the current indications of PPIs in outpatients before admission to hospital, during admission to internal medicine wards, and at discharge.
MATERIAL AND METHODS
An analytic cross-sectional study was carried out, its sample being selected by using the random functions of Excel (Excel 2003) in order to randomly choose one in every four patients treated with PPIs in our internal medicine department during the study period. So, 208 patients from a total of 832 who were treated with PPIs at least once (regardless of dose used) were included in the study. The list of patients was provided by the computer system at the hospital's pharmacy department.
Sample size was estimated using an alpha error of 0.05, a beta error of 0.10 (so that it was possible to detect differences up to 15%), and Fleiss' correction. A loss rate of 15% was assumed. Those case histories that could not be recovered or those who suffered a relevant loss of clinical information were rejected, and new subjects randomly obtained were included in the sample in their place. The study period started on January 1, 2003 and ended on December 31, 2003 at the Internal Medicine Department of the Hospital Universitario de Guadalajara, with a 400-bed capacity. Every medical record was reviewed since arrival in hospital until discharge, information being collected according to a protocol elaborated for the study. This protocol includes demographic variables (sex, age) and clinical variables (pathology and previous treatments, reason for consultation, treatment with PPIs, etc.) (Table II) .
PPI indication was determined for each case after reviewing the medical record, and classified as correct or incorrect. Indications considered appropriate for PPI use are those specified in Nardino et al. (3) Continuous variables are expressed using mean, standard deviation (SD), and range. Qualitative variables are expressed using absolute and relative frequencies. A χ 2 test was used in the comparison of categorical variables. Student's t-test or an analysis of variance was used in the comparison of independent samples means. Values at p < 0.05 were considered significant. The analysis was performed using the statistical package SPSS 11.0.1.
RESULTS
In 2003 there were a total of 1,660 patients admitted to the Internal Medicine Department at Hospital de Guadalajara, of which 832 were under treatment with PPIs, which represents 50.12% of patients. All 208 selected patients had a mean age of 67 ± 19.31 years (range: 16-92) -96 women (46.2%) and 112 men (53.8%). In their medical history before admission the following diseases stand out: Hypertension (47.1%), chronic obstructive pulmonary disease (10%), diabetes mellitus (7%), chronic renal disease (7%), and other (62.2%) (Table II) .
PPI use was not related to patient age, neither before admission nor during admission or at discharge (p = 0.76 before admission, p = 0.256 during admission, p = 0.781 at discharge). No relation to patient sex was found either.
Before admission, 23.6% (49/208) of patients were receiving nonsteroidal anti-inflammatory drugs (NSAIDs), 4.3% (9/208) were receiving corticosteroids, and 57.2% (119/208) were polymedicated; 14.9% (31/208) of patients were not taking any medication before admission.
Treatment before admission
In all, 34.6% (72/208) of patients were receiving treatment with PPIs; 68.1% (49/72) had no suitable indication for them (Fig. 1) . Most common indications were NSAID-induced gastropathy in 11.1% (8/72), ulcer in 9.7% (7/72), and gastritis/gastroesophageal reflux disease (GERD) in 8.3% (6/72). The most frequent incorrect indications were use with antiaggregation/anticoagulation in 26.4% (19/72) , and other reasons in 41.7% (30/72) . In all, 41.7% (30) of patients were taking NSAIDs; PPI correct use reached 43.3% (13/72), its indication being NSAID-induced gastropathy (11.1 % (8) as treatment, and 6.94 % (5) as prophylaxis).
Six point nine percent of patients (5/72) were taking corticosteroids without an indication of gastric prophylaxis in any of the cases; 50% (36/72) were polymedicated, without an indication of PPI use in 72.2% of cases (Table IV) .
Treatment during admission
During admission all patients received PPIs, 73.07% with incorrect use (152/208) (Fig. 1) sons of incorrect use were antiaggregation/anticoagulation in 22.7% (47/208), and other non-specified reasons in 50.7% (105/208) (Table IV) .
Treatment at discharge
At discharge PPI use was reduced to 61.5% (128/208) of patients, of which 61.7% (79/128) had no indication (Fig. 1) .
The most frequent correct indications also were NSAID-related gastropathy in 18.75% (24/128), ulcer in 12.5% (16/128), and gastritis/GERD in 5.5% (7/128). Among incorrect indications antiaggregation/anticoagulation was the reason in 28.1% (36) of patients, and other reasons were used for 32.8% (42) of patients (Table IV) .
Treatment evolution
The evolution of treatment with PPIs was analyzed from admission to hospital to discharge. Treatment with PPIs was maintained in 73.61% of patients, with inappropriate use in 62.27%. PPI therapy was initiated in 58.6% of them, with inadequate use in 61.34%. PPI treatment was retired only in 26.38% of patients who had an inappropriate prescription (Table V) .
In all, 54.83% (17/31) of 31 (14.9%) patients admitted to hospital without treatment were discharged on PPI therapy. An evaluation of the indications for PPI use found acceptable indications in 41.17% (7/17) of patients with the following acceptable indications: Ulcer in 17.64% (3/17), gastritis/gastroesophageal reflux in 11.76% (2/17), and nonsteroideal anti-inflammatory drug-associated gastropathy in 11.76% (2/17). In all 52.63% (10/17) had no indication for PPI use. The most frequent reasons for use without an indication were antiaggregation/anticoagulation in 11.76% (2/17) and other reasons in 47.06% (8/17) .
The risk of being discharged with PPIs has an odds ratio of 2.36 (95% CI 1.24-4.5) (p = 0.008), which is calculated as the difference in number of patients with PPI treatment at discharge versus patients with PPIs at admission. The group of patients who were discharged on PPI therapy was 6.4% (p = 0.47), and were more likely to have an adequate indication than patients receiving it before admission.
Economic impact
All patients studied received a total of 1,589 doses of PPIs, with an average length of stay of 10.77 ± 7.61 days, 514 intravenous and 1,075 oral. This involves spending € 7,573, with an inadequate use of this therapy in 73.07% of cases, which involves an extra expense of € 5,511.67 versus patients who needed no PPIs.
DISCUSSION
In this study we found that there was a very high frequency of unnecessary use of proton pump inhibitors in hospitalized patients and also before admission.
Our findings are consistent with reports previously published (3-7). Our results agree with those reported by Nardino et al. (3) and Noguerado Asensio et al. (7); in their study we observe that 54 and 72.2% of patients received acid-suppressive therapy (AST) during hospitalization, with no indication in 65 and 72.2% of patients, respectively. Of patients receiving therapy, 44 and 26.8% had it prescribed before admission, and 35 and 65.9% of patients continued on PPI therapy at discharge, with an incorrect indication in 67 and 54.1% of patients. In our study, 34.6% of patients were on PPIs with an inadequate indication on 68.1%. PPI therapy initiated during hospitalization was unnecessary in 73.07% of patients. An unnecessary use of PPIs was seen in 61.7 of 61.5% of patients subsequently discharged on PPI therapy. This proves that hospital stay does not contribute to PPI treatment with correct indications. No reference to the reason underlying PPI use was seen in medical records.
In our study, non steroidal anti-inflammatory drug-related gastropathy was the most frequent correct indication in 12.6% of cases (10) (11) (12) (13) (14) (15) . Any NSAID may increase the risk of bleeding, but effects are not cumulative and decrease quickly after treatment discontinuation (12) . PPI therapy has been indicated for long-term preventive treatment, and has proven useful for short NSAID courses and acetylsalicylic acid therapy, mainly in aged patients (16) .
The most frequent inappropriate reason for using PPIs was unclear. In our study, the most frequent reason for inadequate use of PPI therapy was gastrointestinal bleeding prophylaxis due to the administration of anticoagulation or antiaggregation therapy. The indication of PPIs in this situation is unclear; actually, the results reported by Johnsen et bleeding, which is greater when prescribed in association with other treatments, even if these treatments are still not well defined and actions are unknown (17) . Use with antiaggregation, even in low doses, seems to be related with an increased risk of gastrointestinal damage (16, 18, 19) .
Corticosteroid therapy (8, 9 ) is commonly associated with PPI prescriptions for gastrointestinal bleeding prophylaxis, with no scientific evidence supporting this association. In the reports published by Conn et al. (8) and Piper et al. (9) we found no association of gastrointestinal damage with corticosteroid use; also, Nielsen et al. have recently published that prescribing corticosteroids alone has an increased risk for gastrointestinal bleeding with a relative risk of 2.9. Relative risk decreases to 1.9 depending on previous use, age, sex, and underlying pathology (20) , but the authors only recommend special caution if a gastrointestinal bleeding history is present. A study performed by Nielsen et al. (8, 9, 20) shows that only patients who concomitantly used corticosteroids plus NSAIDs had an increased risk for bleeding, the use of PPIs being indicated in such patients with a relative risk of 9.8.
In all, 73% of patients had an inappropriate use of PPIs during hospitalization. The objective reason for incorrect PPI use at admission and discharge was antiaggregation and anticoagulation. Stress ulcer prophylaxis in low-risk patients was the non-objectifiable reason for PPI therapy in hospitalized patients (3, 7) , also this reason is not well documented in medical records. It has been demonstrated that critically ill patients in intensive care units, with prolonged mechanical ventilation and coagulopathy, have an increased risk of gastrointestinal bleeding (21-25); prophylaxis only affects the care of patients with these risk factors for bleeding.
Prophylaxis does not affect patients with polytrauma in intensive care units (26) or low-risk patients (24) . This association has to be reconsidered as there are some studies that reported no benefits on gastrointestinal bleeding or stress ulcer prophylaxis (27, 28) . Even the use of drugs that increase intragastric pH would have a higher risk for nosocomial pneumonia (28) . Routine stress ulcer prophylaxis, even in high-risk patients, seems unjustified. Neither the FDA nor the European Agency for Medication Evaluation have approved this indication to this day (27, 28) . A low but significant reduction of bleeding in the postoperative period has been reported with drug prophylaxis (29) .
Pluripathological patients influence the routine prescription of gastric damage prophylaxis in low-risk patients with PPI treatment. There is no evidence that an association between non-gastrolesive medications and pluripathological patients may lead to increased risk for gastrointestinal bleeding (3, 7) . Nevertheless, Garrido et al. have reported an increased use in the care of bleeding patients with underlying conditions, but lower than related to gastroduodenal ulcer or portal hypertension (30) .
The high prevalence of dyspepsia or gastroesophageal reflux in hospitalized patients contributes to PPI prescriptions (31) (32) (33) , but this reason is usually not clearly documented in the medical record, even being an appropriate indication for PPI use. These patients continued on PPIs after discharge with no clear indication. A study by Rey et al. found that gastroesophageal reflux symptoms have a great impact on healthcare resource use and work absenteeism in Spain, which is in contrast with the popular belief that this is a banal pathology (32) . Actually, hospital admission does not represent a better indication for PPIs versus their prescription before admission (p = 0.47); moreover, the probability of having PPIs included in the therapy regimen after discharge is multiplied by 2.36.
Published reports on the implementation of guidelines for PPI prescription in hospital wards are associated to a better use of these drugs, with a reduction in drug consumption from PPI overuse and of drug interactions and side effects (24, 34) .
In our study there was a very high frequency of incorrect PPI use in hospitalized patients, with such patients maintaining their inappropriate use in spite of admission and with no clear indication after discharge (dyspepsia, antiaggregation in elderly patients with previous ulcers, etc.). Guidelines for an appropriate prescription of PPIs are a most recommendable option, taking into account the possibility of changes in indications derived from the abovementioned reports.
